149 related articles for article (PubMed ID: 15562039)
1. The response to activated protein C after cardiopulmonary bypass: impact of factor V leiden.
Donahue BS
Anesth Analg; 2004 Dec; 99(6):1598-1603. PubMed ID: 15562039
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
3. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Graf LL; Welsh CH; Qamar Z; Marlar RA
Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
[TBL] [Abstract][Full Text] [Related]
4. The association between activated protein C ratio and Factor V Leiden are gender-dependent.
Hansen RS; Nybo M
Clin Chem Lab Med; 2019 Jul; 57(8):1229-1234. PubMed ID: 30903752
[TBL] [Abstract][Full Text] [Related]
5. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
[TBL] [Abstract][Full Text] [Related]
6. Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.
Rühl H; Berens C; Winterhagen FI; Reda S; Müller J; Oldenburg J; Pötzsch B
Circ Res; 2019 Aug; 125(5):523-534. PubMed ID: 31314700
[TBL] [Abstract][Full Text] [Related]
7. Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee.
Moore GW; Castoldi E; Teruya J; Morishita E; Adcock DM
J Thromb Haemost; 2023 Jan; 21(1):164-174. PubMed ID: 36695379
[TBL] [Abstract][Full Text] [Related]
8. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
[TBL] [Abstract][Full Text] [Related]
9. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
Paspatis GA; Sfyridaki A; Papanikolaou N; Triantafyllou K; Livadiotaki A; Kapsoritakis A; Lydataki N
Pathophysiol Haemost Thromb; 2002; 32(1):2-7. PubMed ID: 12214157
[TBL] [Abstract][Full Text] [Related]
10. Factor V(LEIDEN) and cardiopulmonary bypass: investigation of haemostatic parameters and the effect of aprotinin using an ex vivo model.
Linden MD; Schneider M; Erber WN
Perfusion; 2001 Nov; 16(6):476-84. PubMed ID: 11761087
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden: A Comparison of Institutional and National Provider Practices.
Perez Botero J; Majerus JA; Strege AK; Johnson RD; Chen D; Pruthi RK
Am J Clin Pathol; 2017 Jun; 147(6):604-610. PubMed ID: 28472350
[TBL] [Abstract][Full Text] [Related]
12. Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Lindqvist PG; Svensson P; Dahlbäck B
J Thromb Haemost; 2006 Feb; 4(2):361-6. PubMed ID: 16420566
[TBL] [Abstract][Full Text] [Related]
13. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.
Marchiori A; Mosena L; Prins MH; Prandoni P
Haematologica; 2007 Aug; 92(8):1107-14. PubMed ID: 17650440
[TBL] [Abstract][Full Text] [Related]
14. Factor V Leiden: a disorder of factor V anticoagulant function.
Castoldi E; Rosing J
Curr Opin Hematol; 2004 May; 11(3):176-81. PubMed ID: 15257017
[TBL] [Abstract][Full Text] [Related]
15. Factor V Leiden does not affect bleeding in aprotinin recipients after cardiopulmonary bypass.
Boehm J; Grammer JB; Lehnert F; Dietrich W; Wagenpfeil S; Wildhirt SM; Wottke M; Braun S; Lange R; Bauernschmitt R
Anesthesiology; 2007 Apr; 106(4):681-6. PubMed ID: 17413905
[TBL] [Abstract][Full Text] [Related]
16. The procoagulant effects of factor V Leiden may be balanced against decreased levels of factor V and do not reflect in vivo thrombin formation in newborns.
Hyytiäinen S; Wartiovaara-Kautto U; Ulander VM; Kaaja R; Heikinheimo M; Petäjä J
Thromb Haemost; 2006 Mar; 95(3):434-40. PubMed ID: 16525570
[TBL] [Abstract][Full Text] [Related]
17. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease.
Haslam N; Standen GR; Probert CS
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1289-91. PubMed ID: 10563542
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.
Jadaon MM; Dashti AA; Lewis HL
Diagn Mol Pathol; 2010 Sep; 19(3):180-3. PubMed ID: 20736749
[TBL] [Abstract][Full Text] [Related]
19. Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Lincz LF; Lonergan A; Scorgie FE; Rowlings P; Gibson R; Lawrie A; Seldon M
Pathophysiol Haemost Thromb; 2006; 35(6):435-9. PubMed ID: 17565236
[TBL] [Abstract][Full Text] [Related]
20. Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss.
Wüthrich RP; Cicvara-Muzar S; Booy C; Maly FE
Transplantation; 2001 Aug; 72(3):549-50. PubMed ID: 11502996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
